La cadena de opciones muestra datos clave de las opciones de acciones de AnaptysBio a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para AnaptysBio..

AnaptysBio (NASDAQ:ANAB) Bolsa, Cadena de Opciones

ANAPTYSBIO INC

AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Stock Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADTX

ANAB

ANIK

ANNA

AREB

ASBP

CDLX

ELME

FAMI

HEPA

INTC

NOVA

PATH

SGBX

SNES

STGW

YOSH

Intel designa un nuevo CEO y sus acciones suben con fuerza en el premercado. Descubre qué otros valores destacan hoy.

Las acciones de Intel suben más del 10%; 20 acciones que se están moviendo en el premercado

ASST

CCLD

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DWTX

HSDT

HUBC

LSTA

NEHC

NFLX

SEPN

STFS

USEG

Netflix sorprende con un aumento en suscriptores y mejores pronósticos. Descubre también los mayores ganadores y perdedores del premercado.

Acciones de Netflix se disparan alrededor del 15%; 20 acciones que se están moviendo en el premercado de EE.UU.

Long Ideas

Insider Trades

$FET

YUMC

Descubre las recientes compras de insiders en AnaptysBio, Forum Energy y Yum China, indicando posibles oportunidades de inversión.

Insider Trading: Compras en Yum China, AnaptysBio y Forum Energy Technologies

AnaptysBio Inc

Press Releases

Anaptys Announces Stock Repurchase Plan

Management

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Earnings

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Participation in September Investor Conferences

Small Cap

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Health Care

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

DSGN

HLXA

PSTX

XERS

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma

Akebia Therapeutics

Ardelyx

BridgeBio Oncology Therapeutics, Inc. - Common Stock

BridgeBio Oncology

Bicara Therapeutics

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Kodiak Sciences

Kura Oncology

MiMedx Group

Nanobiotix

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Prime Medicine

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Relay Therapeutics

Rezolute

ARS Pharmaceuticals

Tango Therapeutics

Tourmaline Bio

UroGen Pharma

Valneva

Vir Biotechnology

Xencor

Wedbush

Barclays

HC Wainwright & Co.

Comments

AnaptysBio

AnaptysBio (ANAB) Opciones

AnaptysBio (NASDAQ:ANAB) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL